Min-Hee Ryu
Min-Hee Ryu is a gastric cancer and GIST trialist central to the Asian arms of ramucirumab, pembrolizumab, and zolbetuximab studies.
Min-Hee Ryu co-leads gastrointestinal oncology at Asan Medical Center, with steering roles in RAINBOW-Asia, GLOW, and KEYNOTE gastric trials and in GIST tyrosine-kinase-inhibitor sequencing studies.
| Title | Journal | Year |
|---|---|---|
| Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or GEJ adenocarcinoma (GLOW) | Nature Medicine | 2023 |
Pages like this
not linked directly; found by shared links- PersonYoon-Koo Kang
Shares SPOTLIGHT & GLOW, Asan Medical Center, Zolbetuximab, Claudin 18.2.
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- IdeaBiomarker-directed first-line quadruplets in gastric cancer
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonKohei Shitara
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonSun Young Rha
Shares SPOTLIGHT & GLOW, Zolbetuximab, Gastric & gastro-oesophageal junction cancer.
- PersonJeeyun Lee
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- TrialCLARITY-Gastric 01
Shares Ramucirumab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- CompanyKeymed Biosciences (KYM Biosciences)
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer.